ESMO 2024

Adding pembrolizumab to first-line chemoradiotherapy significantly improves the overall survival of women with high-risk, locally advanced cervical cancer.

Supplementing standard perioperative chemotherapy with preoperative chemoradiotherapy does not improve survival in resectable gastric cancer.

Trastuzumab deruxtecan has substantial clinical activity in patients with HER2-positive breast cancer and stable or active brain metastases.

Patients with relapsed/refractory multiple myeloma have better overall survival with BCMA-targeted CAR T-cell therapy than bispecific agents.

PIONeeR trial suggests some durvalumab combinations could be promising for treating NSCLC patients who develop resistance to PD-(L)1 inhibitor therapy.

Triple-B trial suggests a significant PFS benefit of atezolizumab plus a taxane as the chemotherapy backbone in the first-line treatment of metastatic triple-negative breast cancer.

Nonoperative management after complete response to neoadjuvant treatment in patients with pMMR locally advanced rectal carcinoma does not compromise distant recurrence-free survival.

The PRMT5 inhibitor AMG 193 has shown encouraging efficacy and a favorable safety profile in solid tumors with MTAP deletion.

Researchers have developed an AI model that can predict tumor mutations based on pathology images.

Hypofractionated locoregional radiotherapy is noninferior to conventionally fractionated radiotherapy with regard to the risk for arm lymphedema in early breast cancer.

Treatment with ipilimumab plus nivolumab prior to surgery achieved a 3-year disease-free survival of 100% in patients with locally advanced MMR-deficient colon cancer enrolled in the NICHE-2 trial.

Patients with newly diagnosed advanced ovarian cancer do not have longer overall survival with maintenance treatment with niraparib compared with placebo.